These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16130103)

  • 1. Two types of chromosome 1p losses with opposite significance in gliomas.
    Idbaih A; Marie Y; Pierron G; Brennetot C; Hoang-Xuan K; Kujas M; Mokhtari K; Sanson M; Lejeune J; Aurias A; Delattre O; Delattre JY
    Ann Neurol; 2005 Sep; 58(3):483-7. PubMed ID: 16130103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion.
    Law M; Brodsky JE; Babb J; Rosenblum M; Miller DC; Zagzag D; Gruber ML; Johnson G
    J Magn Reson Imaging; 2007 Jun; 25(6):1113-9. PubMed ID: 17520715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosome 1p loss: a favorable prognostic factor in low-grade gliomas.
    Kujas M; Lejeune J; Benouaich-Amiel A; Crinière E; Laigle-Donadey F; Marie Y; Mokhtari K; Polivka M; Bernier M; Chretien F; Couvelard A; Capelle L; Duffau H; Cornu P; Broët P; Thillet J; Carpentier AF; Sanson M; Hoang-Xuan K; Delattre JY
    Ann Neurol; 2005 Aug; 58(2):322-6. PubMed ID: 16049942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between genetic alteration and long-term clinical outcome of patients with oligodendroglial tumors, with identification of a consistent region of deletion on chromosome arm 1p.
    Hashimoto N; Murakami M; Takahashi Y; Fujimoto M; Inazawa J; Mineura K
    Cancer; 2003 May; 97(9):2254-61. PubMed ID: 12712480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
    Weller M; Berger H; Hartmann C; Schramm J; Westphal M; Simon M; Goldbrunner R; Krex D; Steinbach JP; Ostertag CB; Loeffler M; Pietsch T; von Deimling A;
    Clin Cancer Res; 2007 Dec; 13(23):6933-7. PubMed ID: 18056167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation and transcriptional downregulation of the CITED4 gene at 1p34.2 in oligodendroglial tumours with allelic losses on 1p and 19q.
    Tews B; Roerig P; Hartmann C; Hahn M; Felsberg J; Blaschke B; Sabel M; Kunitz A; Toedt G; Neben K; Benner A; von Deimling A; Reifenberger G; Lichter P
    Oncogene; 2007 Jul; 26(34):5010-6. PubMed ID: 17311001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic stratification of patients with anaplastic gliomas according to genetic profile.
    Dehais C; Laigle-Donadey F; Marie Y; Kujas M; Lejeune J; Benouaich-Amiel A; Pedretti M; Polivka M; Xuan KH; Thillet J; Delattre JY; Sanson M
    Cancer; 2006 Oct; 107(8):1891-7. PubMed ID: 16986124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
    Kim SH; Kim H; Kim TS
    Acta Neuropathol; 2005 Jul; 110(1):27-38. PubMed ID: 15920661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].
    Fontaine D; Vandenbos F; Lebrun C; Paquis V; Frenay M
    Rev Neurol (Paris); 2008; 164(6-7):595-604. PubMed ID: 18565359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
    Gresner SM; Rieske P; Wozniak K; Piaskowski S; Jaskolski DJ; Skowronski W; Golanska E; Sikorska B; Liberski PP
    Clin Neuropathol; 2006; 25(1):18-24. PubMed ID: 16465770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.
    Idbaih A; Marie Y; Lucchesi C; Pierron G; Manié E; Raynal V; Mosseri V; Hoang-Xuan K; Kujas M; Brito I; Mokhtari K; Sanson M; Barillot E; Aurias A; Delattre JY; Delattre O
    Int J Cancer; 2008 Apr; 122(8):1778-86. PubMed ID: 18076069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas.
    Reddy KS
    Cancer Genet Cytogenet; 2008 Jul; 184(2):77-86. PubMed ID: 18617055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of chromosome 1p and 19q deletions in glial tumours by interphase FISH on formalin-fixed paraffin-embedded tissue.
    Gonzales M; Dale S; Susman M; Mills J
    J Clin Neurosci; 2006 Jan; 13(1):96-101. PubMed ID: 16410204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral distribution of 1p loss in oligodendroglial tumors.
    Kros JM; van der Weiden M; Zheng PP; Hop WC; van den Bent MJ; Kouwenhoven MC
    J Neuropathol Exp Neurol; 2007 Dec; 66(12):1118-23. PubMed ID: 18090920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Towards a molecular classification of gliomas].
    Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
    Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosome 1p loss evaluation in anaplastic oligodendrogliomas.
    Idbaih A; Kouwenhoven M; Jeuken J; Carpentier C; Gorlia T; Kros JM; French P; Teepen JL; Delattre O; Delattre JY; van den Bent M; Hoang-Xuan K
    Neuropathology; 2008 Aug; 28(4):440-3. PubMed ID: 18312547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy.
    Mariani L; Deiana G; Vassella E; Fathi AR; Murtin C; Arnold M; Vajtai I; Weis J; Siegenthaler P; Schobesberger M; Reinert MM
    J Clin Oncol; 2006 Oct; 24(29):4758-63. PubMed ID: 16966689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma.
    Blesa D; Mollejo M; Ruano Y; de Lope AR; Fiaño C; Ribalta T; García JF; Campos-Martín Y; Hernández-Moneo JL; Cigudosa JC; Meléndez B
    J Neuropathol Exp Neurol; 2009 Mar; 68(3):274-85. PubMed ID: 19225409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated molecular analysis suggests a three-class model for low-grade gliomas: a proof-of-concept study.
    Marko NF; Prayson RA; Barnett GH; Weil RJ
    Genomics; 2010 Jan; 95(1):16-24. PubMed ID: 19835948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.